Mutual Funds Sahi Hai!
To avail the service, you will be redirected to loans.geojitcredits.com
EBITDA increased 112.8% YoY and 9% QoQ to Rs 213 crore in Q1 FY27. EBITDA margin stood at 25.3% compared with 16.1% in Q1 FY26 and 22.8% in Q4 FY26.
Profit before tax increased 169.7% YoY and 3.3% QoQ to Rs 206.6 crore in Q1 FY27.
Total expenses increased 20.14% YoY and declined 4.58% QoQ to Rs 659.63 crore in Q1 FY27. Cost of materials consumed increased 14.5% YoY to Rs 220.67 crore. Employee benefits expense increased 16.17% YoY to Rs 114.29 crore, finance costs increased 15.5% YoY to Rs 7 crore, depreciation and amortisation increased 7.63% YoY to Rs 24.86 crore.
The company recorded its highest-ever quarterly revenue in the UK and Europe at Rs 356 crore, up 74.7% YoY. US and North America revenue increased 15.1% YoY to Rs 377.2 crore, while Australia and New Zealand revenue rose 53.7% YoY to Rs 87.6 crore. Rest-of-World revenue declined 36.8% YoY to Rs 20 crore.
Marksans Pharma said it crossed Rs 1,000 crore in cash for the first time, with cash balance at Rs 1,058 crore as of 30 June 2026 and net cash at Rs 1,031 crore.
The company completed the acquisition of QliniQ B.V. and ABCnow in Europe and said it remains focused on scaling businesses across geographies, accelerating new launches and strengthening its European platform.
Mark Saldanha, managing director of Marksans Pharma, said, “Looking ahead, our focus is clear: to carry this momentum forward, scale our businesses across geographies, accelerate new launches and further strengthen our European platform. We believe the combination of broad-based growth, expanding margins and a strong balance sheet positions Marksans well for the next phase of sustainable growth.”
Mumbai-baased Marksans Pharma is engaged in Research, Manufacturing & Marketing of generic pharmaceutical formulation in the global markets. The company's product portfolio spreads over major therapeutic segments of CVS, CNS, Antidiabetic, Pain Management, Gastroenterological and Anti-allergies. The company is marketing these products globally.
Marksans Pharma Ltd lost 5.24% today to trade at Rs 246.7. The BSE Healthcare index is down 1.34% to quote at 49789.55. The index is up 3.23 % over last one month. Among the other constituents of the index, Anthem Biosciences Ltd decreased 5.17% and Bajaj Healthcare Ltd lost 4.07% on the day. The BSE Healthcare index went up 11.39 % over last one year compared to the 5.84% fall in benchmark SENSEX.
Marksans Pharma Ltd has lost 3.67% over last one month compared to 3.23% gain in BSE Healthcare index and 0.38% rise in the SENSEX. On the BSE, 55408 shares were traded in the counter so far compared with average daily volumes of 1.58 lakh shares in the past one month. The stock hit a record high of Rs 281.4 on 09 Jul 2026. The stock hit a 52-week low of Rs 156 on 30 Mar 2026.
Marksans Pharma has entered into a definitive agreement to acquire 100% of the share capital of ABCnow GmbH, a Germany based pharmaceutical company with front end sales, marketing, and distribution capabilities across German healthcare market. The company will acquire entire shareholding of ABCnow GmbH for a total consideration of € 892,384.
The acquisition marks a strategic step in expanding Marksans' presence across regulated European markets and strengthening its forward-integration strategy through direct, owned market-access capabilities in the European Union.
This acquisition will enable Marksans to use the front-end sales and marketing infrastructure of ABCnow GmbH for marketing its products manufactured in India, UK, and USA regions. It will bolster Marksans' presence in the European markets.
Headquartered in Flensburg, ABCnow GmbH is a pharmaceutical company with front end sales, marketing, and distribution capabilities across German healthcare market. It has a turnover of euro 227,233.69 as on 31 December 2025.
Marksans will acquire entire shareholding of ABCnow GmbH for a total cash consideration of euro 892,384. The acquisition is expected to be completed by 31 July 2026.
Offering the rationale for this acquisition, Marksans Pharma stated that this acquisition will enable the company to use the front-end sales and marketing infrastructure of ABCnow GmbH for marketing its products manufactured in India, UK, and USA regions. It will bolster Marksans’ presence in the European markets.
Marksans Pharma is engaged in the research, manufacturing and marketing of pharmaceutical formulations across regulated and emerging markets, with a strong presence in OTC and prescription products.
The company had reported 63.59% increase in consolidated net profit to Rs 148.13 crore on a 20.84% rise in revenue to Rs 856.11 crore in Q4 FY26 as compared with Q4 FY25.